Dominic Schmidt
Private Equity Investor at Advent Venture Partners LLP
Network origin in Dominic Schmidt first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
University of Cambridge
278
| College/University | Other Consumer Services | 278 |
Advent Venture Partners LLP
 Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom.
18
| Private Company | Investment Managers | 18 |
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom.
17
| Subsidiary | Investment Managers | 17 |
Freie Universität Berlin
15
| College/University | Other Consumer Services | 15 |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom.
13
| Subsidiary | Biotechnology | 13 |
L.E.K. Consulting Group Ltd.
 L.E.K. Consulting Group Ltd. Miscellaneous Commercial ServicesCommercial Services L.E.K. Consulting Group Ltd. operates as a management consulting firm. The company was founded on June 16,2017 and is headquartered in London, the United Kingdom.
4
| Private Company | Miscellaneous Commercial Services | 4 |
Anaveon AG
 Anaveon AG BiotechnologyHealth Technology Anaveon AG engages in the development of immune therapies against cancer. Its compounds promote effector T-cell functions to enhance a patient?s immune system to respond to tumors. The company was founded on December 11, 2017 by Onur Boyman and Andreas Katopodis and is headquartered in Bottmingen, Switzerland.
3
| Holding Company | Biotechnology | 3 |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom.
2
| Private Company | Pharmaceuticals: Major | 2 |
Orbit Biomedical, Inc.
 Orbit Biomedical, Inc. Medical SpecialtiesHealth Technology Orbit Biomedical, Inc. engages in a healthcare company. It aims to revolutionize gene and cell therapy treatment by setting a new standard for precise, targeted surgical delivery. The company was founded by Mike Keane in 2018 and is headquartered in Ambler, PA..
2
| Subsidiary | Medical Specialties | 2 |
Purespring Therapeutics Ltd.
 Purespring Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Purespring Therapeutics Ltd. provides biotechnological research and experimental development services. The company was founded on April 1, 2020 and is headquartered in London, the United Kingdom.
2
| Holding Company | Miscellaneous Commercial Services | 2 |
Forcefield Therapeutics Ltd.
1
| Private Company | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Dominic Schmidt via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| University of Oxford | College/University | Corporate Officer/Principal Undergraduate Degree Graduate Degree Doctorate Degree Doctorate Degree Graduate Degree Graduate Degree Graduate Degree | |
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Chairman Director/Board Member Chief Executive Officer | |
Advent Life Sciences LLP
 Advent Life Sciences LLP BiotechnologyHealth Technology Part of Advent Venture Partners LLP, Advent Life Sciences LLP is a venture capital firm for visionary innovators. The company is based in London, UK. Advent Life Sciences has achieved its first discovery milestone in collaboration with Bristol Myers Squibb, and is focused on the journey from innovative science to an approved medicine or product. The British company has a history of delivering value and is one of the leading venture capital firms in the industry. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Director/Board Member Chief Tech/Sci/R&D Officer | |
Artax Biopharma, Inc.
 Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | Medical Specialties | Director/Board Member Director/Board Member Corporate Officer/Principal | |
Pheno Therapeutics Ltd.
 Pheno Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Pheno Therapeutics Ltd. operates as a biotechnology company. The firm develops remyelinating therapies for the unmet need for a neuroprotective therapy for multiple sclerosis. The company was founded on October 31, 2018 and is headquartered in Edinburgh, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer Chief Executive Officer | |
Tridek-One Therapeutics SAS
 Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
| Stanford University | College/University | Graduate Degree Corporate Officer/Principal Doctorate Degree | |
McKinsey & Co., Inc. (United Kingdom)
 McKinsey & Co., Inc. (United Kingdom) Investment ManagersFinance Part of McKinsey & Co., Inc., McKinsey & Co., Inc. (United Kingdom) is a consulting firm that helps UK manufacturers embrace new technologies for digital transformation and leadership. The company is based in London, UK. Ruben Schaubroeck, McKinsey Digital's new lead for the UK, Belgium, and Netherlands offices, spoke with Thomas Farrar, a manager of communications in the firm's UK office, about the importance of speed and pace for CEOs in this new growth journey. The British company works with organizations that pursue sustainability, inclusion, and economic growth, all at the same time, to achieve strategic foresight and built-in agility in the face of the COVID-19 pandemic and the new trading relationship with the EU. | Investment Managers | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Arrakis Therapeutics, Inc.
 Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Founder Founder Chairman | |
| SYNCONA LIMITED | Investment Trusts/Mutual Funds | Chief Executive Officer Corporate Officer/Principal Chief Executive Officer | |
| University College London | College/University | Undergraduate Degree Doctorate Degree Doctorate Degree | |
| Imperial College London | College/University | Doctorate Degree Undergraduate Degree Undergraduate Degree | |
Avila Therapeutics, Inc.
 Avila Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Avila Therapeutics, Inc. researches and develops covalent drugs. The company was founded in 2007 and is headquartered in Summit, NJ. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Founder | |
| BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Orphalan SA
 Orphalan SA Pharmaceuticals: MajorHealth Technology GMP-Orphan SA engages in the research and development in biotechnology. It focuses on developing and designing drugs for life-threatening and rare diseases. The company was founded by Frederic Marin on July 18, 2011 and is headquartered in Paris, France. | Pharmaceuticals: Major | Chairman Chairman Director/Board Member | |
Inflexion Private Equity Partners LLP
 Inflexion Private Equity Partners LLP Investment ManagersFinance Inflexion Private Equity Partners LLP (Inflexion Private Equity Partners) is a private equity firm founded in 1999 by John Frederick Hartz and Simon Eric Hugh Turner. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
Aleta Biotherapeutics, Inc.
 Aleta Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aleta Biotherapeutics, Inc. engages in the immuno-oncology service that focuses on transforming cellular therapeutics. It allows broad spectrum of cancer indication to be targeted including currently intractable solid tumors. The company was founded by Paul Rennert and Roy Lobb and is headquartered in Natick, MA. | Miscellaneous Commercial Services | Director/Board Member Founder Chief Executive Officer | |
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Biotechnology | Chairman Director/Board Member | |
Zikani Therapeutics, Inc.
 Zikani Therapeutics, Inc. Drugstore ChainsRetail Trade Zikani Therapeutics, Inc. is a preclinical-stage company developing and commercializing novel therapeutics. The company was founded by Lawrence G. Miller and Andrew G. Myers in 2014 and is headquartered in Watertown, MA. | Drugstore Chains | Director/Board Member Chairman | |
| AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member Chairman | |
Luxfold S.A.
 Luxfold S.A. BiotechnologyHealth Technology Luxfold S.A. designs and engineers protein structures. It offers protein three-dimensional structure. The company is headquartered in Luxembourg. | Biotechnology | Director/Board Member Founder | |
Amphista Therapeutics Ltd.
 Amphista Therapeutics Ltd. BiotechnologyHealth Technology Amphista Therapeutics Ltd. is a biopharmaceutical company based in Biocity Glasgow, UK. The British company is focused on creating first-in-class therapeutics that selectively and efficiently degrade and remove disease-causing proteins using targeted protein degradation (TPD). The company's pipeline of novel small molecules is focused on challenging diseases, including cancer. Amphista is a spin-out of Professor Alessio Ciulli's labs at the University of Dundee and is funded by leading life science investors, including Advent Life Sciences, the European Investment Fund, the Scottish Investment Bank, and Biomotiv. The CEO of the company is Nicola Thompson. | Biotechnology | Director/Board Member Director/Board Member | |
MVM Partners LLP
 MVM Partners LLP Investment ManagersFinance MVM Partners LLP (MVM Partners) is a venture capital firm founded in 1997. The firm is headquartered in London, the United Kingdom. | Investment Managers | Private Equity Investor Private Equity Investor | |
| FREELINE THERAPEUTICS HOLDINGS PLC | Biotechnology | Chairman Corporate Officer/Principal | |
| ELOXX PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Eyebiotech Ltd.
 Eyebiotech Ltd. BiotechnologyHealth Technology Eyebiotech Ltd. is a British clinical stage ophthalmology company that treats patients with sight-threatening diseases. The company is based in London, UK. Eyebiotech was founded in 2021 by David R. Guyer and Anthony P. Adamis. David R. Guyer has been the CEO since 2021. | Biotechnology | Founder Private Equity Investor | |
| University of Glasgow | College/University | Doctorate Degree Undergraduate Degree | |
Google UK Ltd.
 Google UK Ltd. Internet Software/ServicesTechnology Services Part of Alphabet, Inc., Google UK Ltd. operates as an internet portal and search index website. The company is based in London, UK. | Internet Software/Services | Sales & Marketing Corporate Officer/Principal | |
Azeria Therapeutics Ltd.
 Azeria Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Azeria Therapeutics Ltd. engages in the research and development of pharmaceutical products. It develops treatments for hormone resistance that targets breast and prostate cancer patients. The company was founded by Jason Carroll in 2017 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| University of Aberdeen | College/University | Undergraduate Degree Undergraduate Degree | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| JAZZ PHARMACEUTICALS PLC | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member | |
Axonics Women's Health Ltd.
 Axonics Women's Health Ltd. Pharmaceuticals: MajorHealth Technology Contura Ltd. specializes in the distribution and sale of healthcare products, both in pharmaceuticals and medical devices. The firm focuses in the fields of urology and urogynaecology. Its products include bulkamid, cystistat, and aquamid. The company was founded by Henry Geoffrey McMillan in 2000 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Corporate Officer/Principal | |
Sanofi Ventures
 Sanofi Ventures Investment ManagersFinance Sanofi Ventures (Sanofi) is a venture capital subsidiary of Sanofi founded in 2001. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Chief Investment Officer Private Equity Investor | |
| King's College London | College/University | Doctorate Degree Graduate Degree | |
NeRRe Therapeutics Ltd.
 NeRRe Therapeutics Ltd. Medical DistributorsDistribution Services NeRRe Therapeutics Ltd. provides clinical and pre clinical drugs for treatment of neuronal hypersensitivity. It develops neurokinin receptor antagonists acquired from GlaxoSmithKline. The company was founded by Emiliangelo Ratti and Mike Trower in 2012 and is headquartered in Stevenage, the United Kingdom. | Medical Distributors | Director/Board Member Director/Board Member | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree Graduate Degree | |
SV Health Investors LLP
 SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Investment Managers | Private Equity Investor Private Equity Analyst | |
| APPLIED GENETIC TECHNOLOGIES CORPORATION | Pharmaceuticals: Generic | Chief Executive Officer Director/Board Member | |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
EUSA Pharma, Inc.
 EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Pharmaceuticals: Major | Director/Board Member Founder | |
| The Trustees of Columbia University in The City of New York | College/University | Graduate Degree Masters Business Admin | |
Chroma Therapeutics Ltd.
 Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Chairman Chief Executive Officer | |
| NIGHTSTAR THERAPEUTICS PLC | Pharmaceuticals: Major | Chief Executive Officer Chairman | |
| Princeton University | College/University | Doctorate Degree Undergraduate Degree | |
| University of Leeds | College/University | Graduate Degree Undergraduate Degree |
Statistics
International
| United Kingdom | 27 |
| United States | 20 |
| France | 3 |
| Netherlands | 2 |
| Luxembourg | 2 |
Sectoral
| Health Technology | 26 |
| Consumer Services | 12 |
| Finance | 7 |
| Commercial Services | 4 |
| Miscellaneous | 2 |
Operational
| Director/Board Member | 270 |
| Corporate Officer/Principal | 106 |
| Undergraduate Degree | 79 |
| Private Equity Investor | 77 |
| Chairman | 61 |
Most connected contacts
| Insiders | |
|---|---|
| Raj Bhikhu Parekh | 50 |
| Martin Murphy | 33 |
| Mohammed Malik | 24 |
| Bryan Geoffrey Morton | 22 |
| Ian James Nicholson | 20 |
| Chris Hollowood | 18 |
| Alan Walts | 17 |
| David Fellows | 16 |
| Katrine Bosley | 15 |
| David Douglas Cleevely | 14 |
| Anne Prener | 14 |
| Hitesh Thakrar | 14 |
| Thomas Sawyer | 13 |
| Satish Jindal | 13 |
| Donald Lee Drakeman | 13 |
- Stock Market
- Insiders
- Dominic Schmidt
- Company connections
